Vivos Q3 2026: $2.75M Nine-Month Loss, Going Concern Doubt, $1.8M Cash
RDGL is trading near its 52-week low of $0.039 (13% above the low).
Summary
Vivos posted a $2.75M nine-month net loss with $1.81M of cash and a reiterated going-concern warning, while continuing to fund itself through Reg A+ share sales and warrant issuances.
Key Events · Earnings and Guidance · RDGL
-
Nine-Month Net Loss Widens to $2.75M
Net loss was $2,746,628 for the nine months ended September 30, 2026, versus $1,987,503 a year earlier, driven partly by an $847,628 loss on share issuance and warrant exchanges.
-
Going Concern Doubt Reiterated
Management states cash of $1,807,350 is insufficient to cover fixed and variable obligations, and the auditor has expressed substantial doubt about the ability to continue as a going concern.
-
Capital Needs of ~$9.0M Over 36 Months
The company requires approximately $3.0 million annually to maintain operations and estimates roughly $9.0 million in additional capital over the next 36 months for FDA trials, clinic expansion and manufacturing.
-
Reg A+ Raises Continue With Warrants
Vivos raised $2,203,800 in March-April 2026 and $1,015,000 in October 2026 through Reg A+ share sales, each paired with warrants struck at $0.075; an October 23 subscription added 12,500,000 shares at $0.08 for $1,000,000 plus 15,000,000 warrants.
Analysis · RDGL · Industrial Applications And Services
Vivos burned $1.76M in operating cash over nine months and ended September with $1.81M on hand — roughly six months of runway at the stated ~$3.0M annual burn. The company again flags substantial doubt about its ability to continue as a going concern and says it needs ~$9.0M over the next 36 months. It is plugging the gap with continuous Reg A+ sales: $2.2M raised in March-April 2026 and another $1.0M in October, each paired with warrants struck at $0.075. The offsetting positive is commercial traction — IsoPet revenue rose to $101,368 from $43,627, and the new in-house APEL facility began shipping in August. The equity story hinges on whether animal-therapy revenue can scale before the next raise.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDGL was trading at $0.04 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $22.6M. The 52-week trading range was $0.04 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.